The approval was supported by data from 2 randomized, double-blind, vehicle-controlled trials that included 736 patients aged 12 years and older with mild to severe plaque psoriasis of the scalp and ...

The U.S. Food and Drug Administration has approved Arcutis Biotherapeutics' Zoryve (roflumilast) topical foam 0.3% for the ...

A total of 432 patients (56.3% women) aged 12 and older with psoriasis on the scalp and body were randomly assigned to two groups, one of which used roflumilast foam 0.3% once a day for eight ...

Once-daily roflumilast foam, 0.3% (Zoryve) significantly improved scalp and body symptoms of plaque psoriasis in a phase III trial. Improvements in scalp itch were also greater for patients ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. By week 8, patients treated with roflumilast saw ...

ZORYVE foam 0.3% shows significant efficacy for scalp and body psoriasis, with FDA review anticipated by May 2025. Arcutis Biotherapeutics, Inc. announced positive results from a pivotal Phase 3 ...

Icotrokinra showed rapid efficacy among adults and adolescents with at least moderate psoriasis. Most participants with scalp psoriasis treated with icotrokinra achieved the study’s primary ...

J&J noted that the therapy also showed high skin clearance rates in subjects having scalp and genital psoriasis, with 66% and 77% of patients, respectively, achieving clear or almost clear skin ...

66% of patients with scalp psoriasis achieved a scalp-specific Investigator's Global Assessment (ss-IGA) c score of 0/1 compared to 11% receiving placebo (P<0.001) at 16 weeks.

Once-daily 0.3% topical roflumilast foam significantly reduced severity in patients with psoriasis of the scalp and body over 8 weeks, with a favorable safety profile. “Use of roflumilast foam ...